Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey NEXT Oncology ( Site 0051), Irving, Texas NEXT Virginia ( Site 0054), Fairfax, Virginia Australia
Blacktown Hospital ( Site 0455), Sydney, New South Wales One Clinical Research ( Site 0454), Nedlands, Western Australia Chile
Pontificia Universidad Catolica de Chile-CICUC ( Site 0103), Santiago, Region M. de Santiago Bradfordhill ( Site 0102), Santiago, Region M. de Santiago Israel
Rambam Health Care Campus ( Site 0252), Haifa Rabin Medical Center ( Site 0253), Petah Tikva Sheba Medical Center ( Site 0251), Ramat Gan South Korea
Seoul National University Hospital ( Site 0501), Seoul Asan Medical Center ( Site 0502), Seoul Spain
Hospital General Universitari Vall d Hebron ( Site 0360), Barcelona Hospital Clinic de Barcelona ( Site 0362), Barcelona Hospital Universitario Fundacion Jimenez Diaz ( Site 0361), Madrid